Evaluation of the safety and efficacy of telmisartan and enalapril,with the potential addition of frusemide,in moderate-renal failure patients with mild-to-moderate hypertension

Abstract

The effect on renal function and efficacy of the angiotensin II AT₁-receptor blocker (ARB), telmisartan, were compared with those of the angiotensin-converting enzyme inhibitor, enalapril, for the treatment of mild-to-moderate hypertension (diastolic blood pressure [DBP] 95—114 mmHg) in the presence of moderate renal failure (creatinine clearance [Ccr] 30—80 ml/minute). The study was multicentre, double-blind, double-dummy and active-controlled in design, with patients randomised in a 2:1 ratio to receive telmisartan or enalapril. After a two-week placebo run-in period, the 71 eligible patients received either telmisartan, 40 mg, or enalapril, 10 mg, once-daily for four weeks. Thereafter, doses were titrated to telmisartan 80 mg or enalapril 20 mg once-daily if supine trough DBP was still ≥90 mmHg. After a further four weeks, dose titration was again performed, as required, to telmisartan, 80 mg, or enalapril, 20 mg, or frusemide was given in addition if the double dose was already being administered. Mean Ccr decreases of 4.6% for telmisartan and 2.8% for enalapril were not clinically significant. Adverse events occurred in 12 (26.7%) telmisartan-treated patients and in 12 (46.2%) patients receiving enalapril. The mean reduction in supine trough DBP from baseline to the last available value was 12.5 mmHg for telmisartan, compared with 11.9 mmHg for enalapril. A full (reduction of ≥10 mmHg) or partial (reduction of 7—9 mmHg) response occurred in 78% of telmisartan patients and 65% of enalapril patients. In the enalapril group, 43% of patients required frusemide, compared with 29% of those in the telmisartan group. In conclusion, telmisartan lacks detrimental effect on renal function, is effective in the treatment of mild-to-moderate hypertension in patients with moderate renal failure, and is comparable to enalapril.

Keywords

telmisartan renal safety creatinine clearance enalapril hypertension

Get full access to this article

View all access options for this article.

References

Brunner HR , Waeber B. , Nussberg J. In: Messerli F , ed. Angiotensin converting enzyme inhibitor in arterial hypertension. Cardiovascular Drug Therapy. Philadelphia: WB Saunders; 1990:732-60.

Nelson EB , Harm SC , Goldberg M. et al. Clinical profile of the first angiotensin II (AT-1 specific) receptor antagonists. In: Laragh JH , Brenner BM , eds. Hypertension: Pathophysiology, Diagnosis, and Management. New York, NY: Raven Press; 1995: 2895-916.

Giatras I. , Lau J. , Levey AS et al. Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997;127:337-45.

Bretzel RG Effects of antihypertensive drugs on renal function in patients with diabetic nephropathy. Am J Hypertens 1997;10(9 Pt 2):208S-17S.

Burnier M. , Brunner HR Angiotensin II receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 1994;3: 537-45.

Geiger H.

Are angiotensin II receptor blockers superior to angiotensin converting enzyme inhibitors with regard to their renoprotective effect?

Nephrol Dial Transplant 1997;12:640-2.

Materson BJ , Preston RA Angiotensin-converting enzyme inhibitors in hypertension. A dozen years of experience. Arch Intern Med 1994;154:513-23.

Textor SC Renal failure related to angiotensin-converting enzyme inhibitors . Semin Nephrol 1997;17:67-76.

Navis G. , Faber HJ , de Zeeuw D. et al. ACE-inhibitors and the kidney: a risk-benefit assessment. Drug Saf 1996;15: 200-11.

10.

Devoy MA , Tomson CR , Edmunds ME et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J Intern Med 1992;232:493-8.

11.

Kon V. , Fogo A. , Ichikawa I. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993;44:545-50.

12.

Ichikawa I. Angiotensin II receptors and renal hemodynamics and function. Blood Press 1996;2(Suppl):19-21.

13.

Ichikawa I.

Will angiotensin II receptor antagonists be renoprotective in humans?

Kidney Int 1996;50:684-92.

14.

Physicians' Desk Reference, 51st edition. Montvale, NJ: Medical Economics ; 1997.

15.

Stangier J. , Schmid J. , Türck D. et al.Absorption, metabolism, and excretion of intravenously and orally administered [14C]telmisartan in healthy volunteers . J Clin Pharmacol 2000 ;40:1312-22.

16.

Stangier J. , Su CAPF , Brickl R. et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000;40: 1365-72.

17.

Weir MR

Are drugs that block the renin-angiotensin system effective and safe in the patients with renal insufficiency?

Am J Hypertens 1999;12(12 Pt 3):195S-203S.

18.

Food and Drug Administration. International Conference on Harmonization; Draft Guidance on Principles for Clinical Evaluation of New Antihypertensive Drugs; Availability. Federal Register 2000;65:4872-1.

19.

Hricik DE , Levine BS , Adrogue HJ et al. Evaluation of enalapril/diltiazem ER in hypertensive patients with coexisting renal dysfunction. J Hum Hypertens 1996;10:769-74.

20.

Kramer BK , Schweda F. , Ramipril Efficacy in Nephropathy Study . Ramipril in non-diabetic renal failure (REIN study). Lancet 1997;350:736-7.

21.

Gansevoort RT , de Zeeuw D. , de Jong PE

Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system?

Kidney Int 1994;45:861-7.

22.

Nielsen S. , Dollerup J. , Nielsen B. et al. Losartan reduces albuminuria in patients with essential hypertension. An enalapril-controlled 3 months' study. Nephrol Dial Transplant 1997;12(Suppl 2):19-23.

23.

Smith DHG , Neutel JM , Morgenstern P. Once-daily telmisartan compared with enalapril in the treatment of hypertension . Adv Ther 1998;15:229-40.

24.

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.

25.

Gomez HJ , Cirillo VJ , Irvin JD Enalapril.A review of human pharmacology. Drugs 1985;30(Suppl 1):13-24.

26.

Oguchi H. , Miyasaka M. , Koiwai T. et al. Pharmacokinetics of temocapril and enalapril in patients with various degrees of renal insufficiency. Clin Pharmacokinet 1993;24:421-7.